Dexcom CEO on Tariffs, US Manufacturing, and Diabetes Care Growth

Navigating Trade Uncertainty and Tariffs

• 💡 Dexcom manufactures a significant portion of its products in the US, including all R&D and product development.
• ⚠️ While affected by tariffs on components purchased outside the US, the company is comfortable navigating these challenges and does not anticipate unexpected impacts.
• 💰 Dexcom plans to absorb any potential cost increases from tariffs, maintaining its position as the lowest-priced product for patients.

Dexcom's Financial Performance and Leadership Transition

• 📈 Despite a 15% stock drop after its earnings call, Dexcom reported a strong second quarter with 15% revenue growth and exceeded operating margin expectations.
• 👤 The CEO, Kevin Sayer, announced his planned stepping down at the end of the year, a transition that had been in place for a long time and was a surprise to some on Wall Street.

Expanding Diabetes Care for Type 2 Patients

• 🎯 Dexcom remains strong in type 1 diabetes care but sees significant growth potential in type 2 diabetes.
• 📊 There are 25 million people in the US with type 2 diabetes not on insulin, a segment where Dexcom's technology provides valuable data and saves healthcare systems money.
• ✅ Expansion of coverage for type 2 patients by major PBMs has created a great growth segment for the company.

US Manufacturing and Component Sourcing

• 🛠️ Dexcom's facility in Mesa, Arizona, assembles units using subcomponents manufactured in Mexico and essential computer chips for sensors.
• 🌍 While some components are sourced internationally, the company is not concerned about tariffs as a primary cost driver and is committed to managing through them without raising prices.